Skip to Main Content

Childhood Cancer Clinical Trials

Recruiting
10-CBA: Access and Distribution of Unlicensed Cryopreserved Cord Blood Units

Full title:

10-CBA: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Study goal:

The primary objective of this study is to examine the incidence of neutrophil recovery after cord transplantation.

In participants receiving a non-licensed CBU: 1) to determine the frequency of graft rejection; 2) to determine the frequency of infection; 3) to determine the frequency of serious infusion reactio; 4) to determine the 1 year survival rate.

Recruiting
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

Full title:

3CAR: B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors

Study goal:

The main purpose of 3CAR is to find out if this type of immunotherapy is safe for pediatric patients with solid tumors. We also want to learn if it is effective in fighting solid tumors.

Diagnosis:

Solid Tumor

Age:

Up to 21 years old

Recruiting
AGCT1531: Carboplatin vs. Cisplatin for germ cell tumors

Full title:

AGCT1531: A Phase 3 Study of Active Surveillance for Low-risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard-risk Pediatric and Adult Patients with Germ Cell Tumors

Study goal:

Watch patients with low-risk germ cell tumors, after tumor removal, treats their tumor as well as if they got the usual treatment of chemotherapy and/or more surgery if needed.

Age:

Standard Risk Group 1: less than 11 years old; Standard risk Group 2: ages 11–25

Recruiting
AGCT1532: BEP Chemotherapy for Germ Cell Tumors

Full title:

AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Study goal:

The purpose of this study is to find out if accelerated chemotherapy will treat germ cell tumors as well as standard. We will also see if both treatments have similar side effects and are well tolerated.

Diagnosis:

Germ cell tumor

Age:

Ages 11–45 years

Recruiting
AML23: Venetoclax and Conventional Chemotherapy for Acute Myeloid Leukemia

Full title:

A Collaborative Phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia

Study goal:

Study the side effects of using venetoclax and chemotherapy to treat children with AML; learn more about how this treatment works

Age:

Older than 28 days and younger than 22 years

Recruiting
ANBL1821: Eflornithine with Chemo-Immunotherapy for Children with Advanced Neuroblastoma

Full title:

Phase 2 Randomized Study of Irinotecan/ Temozolomide/ Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Study goal:

The main purpose of this study is to find out the good and bad effects of eflornithine combined with irinotecan, temozolomide, and dinutuximab in children and young adults with relapsed or refractory neuroblastoma.

Diagnosis:

Neuroblastoma

Age:

At least 1 year old

Clinical trial categories:

Childhood Cancer Neuroblastoma Solid Tumors
Recruiting
ANGIO-A: Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumors

Full title:

Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Study goal:

In Part 1 of this study, we will see if sorafenib, cyclophosphamide, bevacizumab, and atezolizumab can be given safely together without causing serious side effects. Part 2 of the study will find out how well these medicines work in hepatocellular carcinoma, fibrolamellar carcinoma, desmoplastic small round cell tumors, and malignant rhabdoid tumors.

Diagnosis:

Solid tumors, hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomas, malignant rhabdoid tumors, desmoplastic small round cell tumors

Age:

1-30 years old

Recruiting
AOST2032: Cabozantinib with Chemotherapy for Osteosarcoma

Full title:

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Study goal:

Find the highest dose of cabozantinib that can be given safely along with MAP chemotherapy; compare the effects of cabozantinib along with MAP and surgery versus MAP and surgery alone to find out which is better.

Diagnosis:

Osteosarcoma

Age:

Less than 40 years old

Clinical trial categories:

Childhood Cancer Osteosarcoma Solid Tumors
Recruiting
APAL2020D: Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Full title:

A Randomized Phase 3 Trial of Fludarabine/ Cytarabine/ Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Study goal:

To find out if adding venetoclax to standard chemotherapy leads to improved survival for children and young adults with relapsed AML.

Age:

29 days old to 21 years old

Recruiting
ARST2032: Very Low-Risk and Low-Risk Rhabdomyosarcoma Study

Full title:

A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

Study goal:

Compare the effects of giving less chemotherapy drugs to people with VLR-RMS, who do not have the MYOD1 or TP53 mutation, to find out which is better; to find out how well people with LR-RMS, without MYOD1 or TP53 mutations, respond to standard chemotherapy, and to see the effects of giving chemotherapy drugs for a longer amount of time. We want to see if patients with RMS and the MYOD1 or TP53 mutation benefit from longer therapy than the shorter treatment we give to VLR or LR patients.

Diagnosis:

Rhabdomyosarcoma

Age:

Up to 21 years old

Clinical trial categories:

Childhood Cancer Rhabdomyosarcoma Solid Tumors
Recruiting
CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

Full title:

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Study goal:

The main purpose of this study is to find the highest dose of CD123-CAR T cells that is safe to give patients with AML.  We also want to study the side effects of the treatment and learn how effective it is in fighting this type of cancer.

Age:

21 years old or younger

Recruiting
CCSS: Childhood Cancer Survivor Study Clinical Trial

Study goal:

The purpose of this study is to learn about the health of persons who were treated for cancer, leukemia, tumors, or other similar illness as children. We are interested in studying the possibility of second cancers, long-term effects of chemotherapy (cancer fighting drugs) and radiation therapy, and your child’s family history of cancer. Information collected will help researchers learn how to develop health programs for cancer survivors. 

Diagnosis:

Childhood cancer 

Age:

Age less than 21 years at the time of diagnosis of cancer

Clinical trial categories:

Childhood Cancer
Recruiting
CONNECT: Social Experiences of Adolescents and Young Adults with Cancer

Full title:

Social Experiences of Adolescents and Young Adults with Cancer

Study goal:

The main goal of this study is to learn how cancer treatment affects relationships in teens and young adults with cancer.

Diagnosis:

Non-therapeutic

Age:

15 to 22 years old

Clinical trial categories:

Childhood Cancer
Recruiting
CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms

Full title:

A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms 

Study goal:

This study will help us understand the effects of CPX-351 treatment in patients with MDS and AML.

Age:

1-22 years old

Recruiting
DIRECT70: CAR T–Cell Therapy for Children with Blood Malignancies

Full title:

CAR T–Cell Therapy Directed to CD70 for Pediatric Patients with Hematological Malignancies (DIRECT70)

Study goal:

The purpose of this study is to find the highest dose of CD70+ CAR cells that is safe to give to patients with CD70+ blood cancers.

Diagnosis:

ALL, AML, MDS, Lymphoma

Age:

Up to 21 years old

Recruiting
EPCP1: Exploring the Role of Palliative Care in Childhood Cancer Patients

Full title:

Exploring the Role of Palliative Care in Phase 1 Enrolled Pediatric Oncology Patients

Study goal:

The main purpose of this study is to learn about a caregiver’s experience of enrolling their child in a clinical trial.

Age:

Caregiver is 18 years of age or older

Clinical trial categories:

Childhood Cancer
Recruiting
FLOPET: 18F-DA PET Scans for Neuroblastoma and Pheochromocytoma Tumors

Full title:

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

Study goal:

The main goal of this study is to test the safety of 18F-DA in children with neuroblastoma or pheochromocytoma.

Diagnosis:

Neuroblastoma, pheochromocytoma

Age:

At least 1 year old

Recruiting
Published results
G4K: Genomes for Kids

Study goal:

The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.

Recruiting
GENEFU: Long-Term Follow-Up of Patients Who Received Gene Therapy or Gene Marked Products

Full title:

Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

Study goal:

To find out if infants, children, and young adults develop any side effects months or years after receiving a gene transfer product as part of a research study or related treatment at St. Jude Children's Research Hospital.

Recruiting
HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors

Full title:

Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

Study goal:

The main purpose of this study is to find out what happens, good and bad, to memory and learning when the hippocampus is avoided during proton therapy radiation.

Diagnosis:

Low-grade glioma

Age:

At least 6 years old and younger than 22

Recruiting
HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors

Full title:

Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy

Study goal:

The main goal of this study is to encourage you to maintain healthy lifestyle behaviors and avoid risky behaviors after your cancer therapy is over.

Age:

5 to 17 years old

Clinical trial categories:

Childhood Cancer
Recruiting
INOMRD: Inotuzumab Ozogamicin for High-Risk B-Cell Acute Lymphoblastic Leukemia

Full title:

Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia

Study goal:

The main goal of this study is to learn about the good and bad side effects of inotuzumab ozogamicin in children with this type of leukemia and to find out how well the drug works to get rid of the disease.

Age:

Younger than 22 years old

Recruiting
IPACTR: International Pediatric Adrenocortical Tumor Registry

Full title:

International Pediatric Adrenocortical Tumor Registry

Study goal:

The main goal of IPACTR is to collect relevant clinical and biological data, including blood and tissue samples, to help researchers better understand the 1) common signs and symptoms of ACT, 2) length of time between the first signs and symptoms and diagnosis of ACT, 3) how genetic conditions such as Li-Fraumeni and Beckwith-Wiedemann syndrome make a person more likely to develop ACT, 4) family history of cancer in relatives of children with ACT, 5) how children with ACT in different parts of the world are treated, and 6) how the genetic makeup affects survival in children and relatives with ACT.

Diagnosis:

Adrenocortical tumors (carcinoma and adenoma)

Age:

21 years of age or younger at diagnosis

Recruiting
LOXORET: Phase 1/2 Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

Full title:

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors 

Study goal:

The main goal of this study is to test the safety of selpercatinib in children and adolescents with solid tumors or brain and spinal cord tumors. Researchers also want to learn how the drug affects cancer in children and the best, most effective dose.

Age:

6 months to 21 years old

Clinical trial categories:

Childhood Cancer Brain Tumors Solid Tumors
Recruiting
Loc3CAR: B7-H3-Specific CAR T-Cell Therapy for Children with Primary CNS Tumors

Full title:

Locoregional Delivery of B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cells for Pediatric Patients with Primary CNS Tumors

Study goal:

The purpose of this study is to find: 1) the largest dose of Loc3CAR T cells that is safe to give patients with B7-H3–positive brain tumors; 2) the side effects of Loc3CAR T cells; 3) the effect Loc3CAR T cells have on brain tumors. This trial will help scientists better understand how the immune system fights this kind of tumor. What we learn from this study could help us create better treatments.

Diagnosis:

Brain tumorsDIPG, DMG

Age:

Up to 21 years old

Clinical trial categories:

Childhood Cancer Brain Tumors Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse Midline Glioma

Recruiting
MACMEL: A Study to Analyze Melanoma Lesions in Children and Teens

Full title:

Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

Study goal:

Researchers in this study want to learn more about melanoma tumors in children and adolescents. They want to understand the different types of tumors better and learn how each type responds to treatment. They also want to find out why some children and teens are more likely to develop melanoma. Doctors hope this information will help them decide which melanoma treatments are most effective. They also hope to use this information to develop new treatments for children with melanoma.

Diagnosis:

Melanoma

Age:

Up to 18 years old

Clinical trial categories:

Childhood Cancer Melanoma Solid Tumors
Recruiting
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

Full title:

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

Study goal:

The main goal of this study is to learn the largest dose of memory CAR T cells that can be safely given. Researchers also want to learn about the way memory CAR T cells act in the body and how effectively they treat this type of cancer.

Age:

Donor: At least 19 years old; Recipient: 21 years or younger

Recruiting
NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Full title:

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

Study goal:

The primary purpose of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting.

Diagnosis:

Leukemia and other blood diseases

Recruiting
NMDPD: Marrow Donor Database Clinical Trial

Full title:

National Marrow Donor Program: A Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation

Study goal:

The purpose of this study is to collect information from the medical records of patients receiving an unrelated transplant. Information in this research database may be helpful towards improving the results of future patients receiving transplants.

Recruiting
NRSTS2021: A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy, and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Full title:

A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy, and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Study goal:

The purpose of this clinical trial is to find better treatments for NRSTS patients who are intermediate- and high-risk. Our goal is to lower the risk of the tumor coming back after treatment, while using treatments with fewer risks of long-term side effects.

Diagnosis:

Non-rhabdomyosarcoma soft tissue sarcoma, adipocytic neoplasm, liposarcoma, synovial sarcoma, MPNST, undifferentiated sarcoma

Age:

Up to 30 years old.

Recruiting
ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

Full title:

A Randomized Phase 1/2 Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

Study goal:

The main goal of this study is to test new experimental drugs in hopes of finding a treatment that may work against tumors that have come back or that have not responded to standard therapy in children, adolescents and young adults.

Age:

12 months to 30 years old

Recruiting
PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy

Full title:

Mobile Technology to Improve Pain and Symptoms in Children With Cancer

Study goal:

The main goal of this research study is to help us learn how to better treat pain and symptoms in children going through chemotherapy cancer treatment.

Age:

8 to 18 years old

Recruiting
PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

Full title:

A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; anti PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG), DIPGs and Hypermutated Brain Tumors

Study goal:

To study the side effects and best dose of MK-3475 (pembrolizumab) and to see how well it works in treating younger patients with high-grade gliomas (brain tumors), diffuse intrinsic pontine gliomas (brain stem tumors), or hypermutated brain tumors that have come back, progressed or have not responded to previous treatment

Diagnosis:

Recurrent, progressive, or refractory high-grade gliomas

Age:

Participant is 1 to 18 years of age

Recruiting
PBTC48: Optune Device in Children with Certain High-Grade Glioma or Ependymoma Brain Tumors

Full title:

Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma

Study goal:

The main purpose of this study is to see if the Optune System is safe to use in children. Researchers also want to find out if children are able to wear the device as instructed.

Diagnosis:

High-grade glioma (HGG), ependymoma

Age:

Between 5 and 21 years old

Recruiting
PBTC49: Phase 1 Trial of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

Full title:

Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

Study goal:

 To see if savolitinib is safe and tolerable in children with brain tumors

Age:

Between 5 years old and 21 years old

Recruiting
PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

Full title:

A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study goal:

The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.

Age:

12 months to 30 years

Recruiting
PEPN2111: Phase 1/2 Trial of CBL0137 for Relapsed or Refractory Solid Tumors and Lymphoma

Full title:

A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Study goal:

The main purpose of this study is to find the highest, safest dose of CBL0137 that can be given to children, teens and young adults with solid tumors or lymphoma.

Age:

12 months to 21 years old with diagnosis of relapsed or refractory solid tumor or lymphoma (including CNS tumors) or progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy; 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Recruiting
RAVAML: Revumenib, Azacitidine, and Venetoclax for Pediatric AML

Full title:

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia

Study goal:

Find out the dose of revumenib, azacitidine and venetoclax that can be used to safely treat children, adolescents, and young adults with refractory or relapsed AML or ALAL

Diagnosis:

Acute myeloid leukemia or acute leukemia of ambiguous lineage

Age:

1–30 years old

Recruiting
RBAPP: Smartphone App for Retinoblastoma

Full title:

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

Study goal:

The main purpose of this study is to find out the best way to use the CRADLE app to identify leukocoria in children with retinoblastoma, congenital cataracts and glaucoma.

Diagnosis:

Retinoblastoma

Age:

7 years old or younger

Clinical trial categories:

Childhood Cancer Retinoblastoma
Recruiting
REF2HCT: Haploidentical Bone Marrow Transplant for Relapsed or Refractory Leukemia, Lymphoma, or Myelodysplastic Syndrome After an Earlier Transplant

Full title:

Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

Study goal:

The main goal of this study is to learn about the good and bad effects of transplanting blood cells donated by a family member to children and young adults with cancer that has come back or did not improve after a previous bone marrow transplant.

Diagnosis:

Leukemia, Lymphoma, Myeloid sarcoma, Myelodysplastic syndrome, Juvenile Myelomonocytic Leukemia, Non-Hodgkin Lymphoma

Age:

21 years old and younger

Recruiting
RMS2021: Using Molecular Risk Stratification and Liposomal Irinotecan in Children with Intermediate-risk and High-risk Rhabdomyosarcoma

Full title:

A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children with Intermediate- and High-risk Disease

Study goal:

To find the most effective treatment for each risk group of rhabdomyosarcoma patients

Diagnosis:

Rhabdomyosarcoma

Age:

Up to 21 years old

Clinical trial categories:

Childhood Cancer Rhabdomyosarcoma Solid Tumors
Recruiting
RT3CR: Proton Therapy for Pediatric Craniopharyngioma

Full title:

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Study goal:

The main goal of this study is to learn if proton therapy will treat patients with craniopharyngioma brain tumors effectively and reduce side effects compared to traditional forms of radiation therapy.

Diagnosis:

Craniopharyngioma

Age:

21 years old or younger

Clinical trial categories:

Childhood Cancer Craniopharyngioma Brain Tumors
Recruiting
SELCLAX: A Study of Venetoclax and Selinexor with Chemotherapy in Children with AML

Full title:

A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Study goal:

The main goals of this study are to test the safety of venetoclax and selinexor and find the highest dose that is safe to give when combined with chemotherapy drugs. Researchers also want to find out about any side effects and learn how the treatment affects your body.

Age:

30 years or younger

Recruiting
SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma

Full title:

SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma

Study goal:

The main goal of this study is to test the experimental drug mirdametinib in hopes of finding a treatment that may be effective against low-grade glioma brain tumors in children, adolescents and young adults.

Diagnosis:

Low-grade glioma

Age:

At least 2 years old and younger than 25 years old.

Recruiting
SJFAMILY: Study of Cancer in Families

Full title:

Familial Investigations of Childhood Cancer Predisposition

Study goal:

The main purpose of this trial is to learn about the genetic causes of cancer. 

Age:

Younger than 50 years old

Clinical trial categories:

Genetic Syndromes Childhood Cancer
Recruiting
SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Full title:

SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Study goal:

To establish a lifetime group of childhood cancer survivors treated at St. Jude Children’s Research Hospital and to evaluate health outcomes in aging survivors of pediatric cancer

Age:

Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude

Clinical trial categories:

Childhood Cancer Brain Tumors Leukemia Solid Tumors
Recruiting
SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Full title:

SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Study goal:

To collect information about the effects of childhood cancer and its treatment on the patients who are treated or followed after treatment for childhood cancer at St. Jude Children’s Research Hospital

Clinical trial categories:

Childhood Cancer Brain Tumors Leukemia Solid Tumors
Recruiting
SJPROTON2: Effects of Patient Positioning on Accuracy of Pediatric Proton Therapy

Full title:

Estimating Setup Uncertainty in Pediatric Proton Therapy Using Volumetric Images

Study goal:

The main goal of this study is to collect information about how a patient is positioned and set up for radiation therapy.

Clinical trial categories:

Childhood Cancer Brain Tumors Lymphoma Solid Tumors
Recruiting
SJWT21: Study of Proton Therapy in Patients with Wilms Tumor following Nephrectomy

Full title:

Multi-Center Trial Sponsored by St. Jude Children's Research Hospital for the Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

Study goal:

The main goal of this study is to find out if proton therapy causes fewer long-term side effects in patients with Wilms tumor than standard radiation treatment.

Diagnosis:

Wilms Tumor

Clinical trial categories:

Wilms Tumor Childhood Cancer Solid Tumors
Recruiting
SJiMB21: Risk-Based Medulloblastoma Treatment for Infants and Young Children

Full title:

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma

Study goal:

This study uses a risk-directed approach to find out which types of treatment will work best and have the fewest side effects for infants and children with medulloblastoma.

Diagnosis:

Medulloblastoma

Age:

Birth to 5 years old

Clinical trial categories:

Childhood Cancer Medulloblastoma Brain Tumors
Recruiting
SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors

Full title:

Components of Social Functioning in Survivors of Pediatric Brain Tumors

Study goal:

Examine the impact of social-cognitive and neurocognitive abilities on social functioning in survivors of pediatric brain tumors

Diagnosis:

Brain tumor

Clinical trial categories:

Childhood Cancer Brain Tumors
Recruiting
TBANK: Collecting, Banking, and Distributing Human Tissue Samples in St. Jude Biorepository

Full title:

TBANK: Protocol for Collecting, Banking, and Distributing Human Tissue Samples: St. Jude Children’s Research Hospital Biorepository

Study goal:

To provide a high-quality repository of tumor and normal samples to facilitate translational research performed by St Jude faculty and their collaborators

Diagnosis:

All diseases

Recruiting
TRIALS: Transfusional Iron Overload Among Leukemia Survivors

Full title:

TRIALS: Transfusional Iron Overload Among Leukemia Survivors

Study goal:

1) To find out how many long-term survivors of leukemia have iron overload by using MRI testing. 2) To study how the number of red blood cell transfusions you received determines whether you have iron overload. 3) To explore how your age at the time of cancer therapy, the length of time from therapy, and gender affects whether you develop iron overload. 4) To find out if iron overload is causing problems with your organs.

Diagnosis:

Leukemia Survivors

Recruiting
U-CHAT: Understanding Communication in Health Care to Achieve Trust

Full title:

Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

Study goal:

To identify recurrent verbal and nonverbal communication techniques employed by pediatric oncologists in the delivery of difficult prognostic information to parents through content analysis of audio recorded conversations between pediatric oncologists and parents of children with high-risk cancer at times of disease re-evaluation

Diagnosis:

Non-therapeutic

Age:

Patients: Age 30 or younger
Parents: Age 18 or older

Clinical trial categories:

Childhood Cancer Solid Tumors Brain Tumors
Recruiting
cHOD17: Risk-Adapted Therapy for Children and Young Adults with Hodgkin Lymphoma

Full title:

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Study goal:

The main goal of this study is to see if this approach can reduce treatment-related late effects in children and young adults with Hodgkin lymphoma.

Diagnosis:

Hodgkin Lymphoma

Age:

21 years or younger (low-risk patients)
25 years or younger (high-risk patients)

Clinical trial categories:

Childhood Cancer Hodgkin Lymphoma Lymphoma